BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31766351)

  • 21. B and T cell prolymphocytic leukaemia.
    Cross M; Dearden C
    Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Andersson EI; Brück O; Braun T; Mannisto S; Saikko L; Lagström S; Ellonen P; Leppä S; Herling M; Kovanen PE; Mustjoki S
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32188095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia.
    Bergmann AK; Schneppenheim S; Seifert M; Betts MJ; Haake A; Lopez C; Maria Murga Penas E; Vater I; Jayne S; Dyer MJ; Schrappe M; Dührsen U; Ammerpohl O; Russell RB; Küppers R; Dürig J; Siebert R
    Genes Chromosomes Cancer; 2014 Apr; 53(4):309-16. PubMed ID: 24446122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deregulation of the Interleukin-7 Signaling Pathway in Lymphoid Malignancies.
    Lodewijckx I; Cools J
    Pharmaceuticals (Basel); 2021 May; 14(5):. PubMed ID: 34066732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Down-regulation of SHP1 and up-regulation of negative regulators of JAK/STAT signaling in HTLV-1 transformed cell lines and freshly transformed human peripheral blood CD4+ T-cells.
    Cheng J; Zhang D; Zhou C; Marasco WA
    Leuk Res; 2004 Jan; 28(1):71-82. PubMed ID: 14630083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in the understanding and management of T-cell prolymphocytic leukemia.
    Laribi K; Lemaire P; Sandrini J; Baugier de Materre A
    Oncotarget; 2017 Nov; 8(61):104664-104686. PubMed ID: 29262669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
    Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
    Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differentially expressed JAK-STAT signaling pathway genes and target microRNAs in the spleen of necrotic enteritis-afflicted chicken lines.
    Truong AD; Rengaraj D; Hong Y; Hoang CT; Hong YH; Lillehoj HS
    Res Vet Sci; 2017 Dec; 115():235-243. PubMed ID: 28525837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Canonical and non-canonical JAK/STAT transcriptional targets may be involved in distinct and overlapping cellular processes.
    Tsurumi A; Zhao C; Li WX
    BMC Genomics; 2017 Sep; 18(1):718. PubMed ID: 28893190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia.
    Huang L; Liu D; Wang N; Ling S; Tang Y; Wu J; Hao L; Luo H; Hu X; Sheng L; Zhu L; Wang D; Luo Y; Shang Z; Xiao M; Mao X; Zhou K; Cao L; Dong L; Zheng X; Sui P; He J; Mo S; Yan J; Ao Q; Qiu L; Zhou H; Liu Q; Zhang H; Li J; Jin J; Fu L; Zhao W; Chen J; Du X; Qing G; Liu H; Liu X; Huang G; Ma D; Zhou J; Wang QF
    Cell Res; 2018 Feb; 28(2):172-186. PubMed ID: 29148541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
    Alunno A; Padjen I; Fanouriakis A; Boumpas DT
    Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mining for JAK-STAT mutations in cancer.
    Constantinescu SN; Girardot M; Pecquet C
    Trends Biochem Sci; 2008 Mar; 33(3):122-31. PubMed ID: 18291658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.
    de Bock CE; Demeyer S; Degryse S; Verbeke D; Sweron B; Gielen O; Vandepoel R; Vicente C; Vanden Bempt M; Dagklis A; Geerdens E; Bornschein S; Gijsbers R; Soulier J; Meijerink JP; Heinäniemi M; Teppo S; Bouvy-Liivrand M; Lohi O; Radaelli E; Cools J
    Cancer Discov; 2018 May; 8(5):616-631. PubMed ID: 29496663
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Grabarek BO; Wcisło-Dziadecka D; Gola J
    Postepy Dermatol Alergol; 2020 Aug; 37(4):513-519. PubMed ID: 32994772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Research Advances of Genetics, Diagnosis and Treatment of T-cell Prolymphocytic Leukemia--Review].
    Lai MF; Li F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1977-1981. PubMed ID: 34893145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Comprehensive Update on Molecular and Cytogenetic Abnormalities in T-cell Prolymphocytic Leukemia (T-pll).
    Delgado P; Starshak P; Rao N; Tirado CA
    J Assoc Genet Technol; 2012; 38(4):193-8. PubMed ID: 23183331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-Cell Prolymphocytic Leukemia: An Overview of Current and Future Approaches.
    Colon Ramos A; Tarekegn K; Aujla A; Garcia de de Jesus K; Gupta S
    Cureus; 2021 Feb; 13(2):e13237. PubMed ID: 33728186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
    Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
    J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors.
    Govaerts I; Jacobs K; Vandepoel R; Cools J
    Hemasphere; 2019 Dec; 3(6):e313. PubMed ID: 31976485
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.